Welcome to our dedicated page for Omeros news (Ticker: OMER), a resource for investors and traders seeking the latest updates and insights on Omeros stock.
Omeros Corporation (OMER) is a clinical-stage biopharmaceutical company pioneering therapies for immunologic disorders and complement-mediated diseases. This page provides investors and researchers with essential updates on the company's clinical trials, regulatory progress, and strategic developments.
Access timely announcements including FDA submissions, clinical trial results, partnership agreements, and financial reports. Our curated news collection helps stakeholders track Omeros' advancements in targeting the complement system and addressing unmet medical needs.
Bookmark this page for centralized access to verified updates about OMER's pipeline candidates, including its lead monoclonal antibody therapy. Stay informed about developments in hematologic, nephrologic, and central nervous system disorders through our comprehensive news monitoring.
Omeros Corporation (NASDAQ: OMER) announced positive interim results from its Phase 1b trial of OMS906, a MASP-3 inhibitor for treating paroxysmal nocturnal hemoglobinuria (PNH). The study showed significant improvements in hemoglobin (Hgb) and lactate dehydrogenase (LDH). Notably, all patients treated with OMS906 experienced an increase in Hgb of at least 4.0 g/dL after two doses, with a mean increase of 4.75 g/dL (p < 0.001). After three doses, the mean increase reached 6.27 g/dL (p = 0.005). Importantly, all patients remained transfusion-free throughout the observation period. OMS906 demonstrated good tolerability with no safety concerns reported. Omeros aims to expand its clinical trials and anticipates preliminary results from additional studies in the coming months.
Omeros Corporation (Nasdaq: OMER) has secured a $6.69 million grant from the National Institute on Drug Abuse to advance its proprietary PDE7 inhibitor, OMS527, aimed at treating cocaine use disorder (CUD). The funding, awarded on April 7, 2023, will be utilized for both preclinical studies and a clinical trial assessing OMS527's safety and efficacy in patients suffering from CUD, particularly those using cocaine concurrently. The research objectives include interaction studies in animal models and a randomized clinical study comparing OMS527 to placebo. This initiative arises from the growing societal crisis of substance use disorders, with 1.4 million Americans estimated to have CUD. Omeros’ drug has previously demonstrated tolerability in Phase 1 trials, showcasing its potential in combating addiction-related conditions.
Omeros Corporation (Nasdaq: OMER) reported a net income of $128.7 million, or $2.05 per share, for Q4 2022, reversing a prior loss of $17.5 million in Q3 2022. However, the net loss from continuing operations narrowed to $46.0 million, down from $54.8 million. The company earned $17.9 million in royalties from OMIDRIA in Q4, with total cash resources at $194.9 million. A pivotal milestone was the $200 million payment from Rayner, triggered by OMIDRIA sales. Additionally, Omeros plans to resubmit its BLA for narsoplimab and expects crucial data from ongoing trials in 2023.
FAQ
What is the current stock price of Omeros (OMER)?
What is the market cap of Omeros (OMER)?
